Clinical Trial

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-11-10; most recent amendment 2026-03-25.
Status change: Recruiting → Active, Not Recruiting 2026-03-25
Status change: Not Yet Recruiting → Recruiting 2022-04-11
Trial Details
NCT Number NCT05130177
Lead Sponsor Diwakar Davar
Collaborators: Arcus Biosciences, Inc.
Conditions Melanoma
Enrollment 8 participants
Start Date 2022-03-16
Primary Completion 2026-02-06 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-31